OBJECTIVE: To test the validity and generalizability of the Ocular Hypertension Treatment Study (OHTS) prediction model for the development of primary open-angle glaucoma (POAG) in a large independent sample of untreated ocular hypertensive individuals and to develop a quantitative calculator to estimate the 5-year risk that an individual with ocular hypertension will develop POAG. DESIGN: A prediction model was developed from the observation group of the OHTS and then tested on the placebo group of the European Glaucoma Prevention Study (EGPS) using a z statistic to compare hazard ratios, a c statistic for discrimination, and a calibration chi2 for systematic overestimation/underestimation of predicted risk. The 2 study samples were pooled to increase precision and generalizability of a 5-year predictive model for developing POAG. PARTICIPANTS: The OHTS observation group (n = 819; 6.6 years' median follow-up) and EGPS placebo group (n = 500; 4.8 years' median follow-up). TESTING: Data were collected on demographic characteristics, medical history, ocular examination visual fields (VFs), and optic disc photographs. MAIN OUTCOME MEASURE: Development of reproducible VF abnormality or optic disc progression as determined by masked readers and attributed to POAG by a masked end point committee. RESULTS: The same predictors for the development of POAG were identified independently in both the OHTS observation group and the EGPS placebo group-baseline age, intraocular pressure, central corneal thickness, vertical cup-to-disc ratio, and Humphrey VF pattern standard deviation. The pooled multivariate model for the development of POAG had good discrimination (c statistic, 0.74) and accurate estimation of POAG risk (calibration chi2, 7.05). CONCLUSIONS: The OHTS prediction model was validated in the EGPS placebo group. A calculator to estimate the 5-year risk of developing POAG, based on the pooled OHTS-EGPS predictive model, has high precision and will be useful for clinicians and patients in deciding the frequency of tests and examinations during follow-up and advisability of initiating preventive treatment.
OBJECTIVE: To test the validity and generalizability of the Ocular Hypertension Treatment Study (OHTS) prediction model for the development of primary open-angle glaucoma (POAG) in a large independent sample of untreated ocular hypertensive individuals and to develop a quantitative calculator to estimate the 5-year risk that an individual with ocular hypertension will develop POAG. DESIGN: A prediction model was developed from the observation group of the OHTS and then tested on the placebo group of the European Glaucoma Prevention Study (EGPS) using a z statistic to compare hazard ratios, a c statistic for discrimination, and a calibration chi2 for systematic overestimation/underestimation of predicted risk. The 2 study samples were pooled to increase precision and generalizability of a 5-year predictive model for developing POAG. PARTICIPANTS: The OHTS observation group (n = 819; 6.6 years' median follow-up) and EGPS placebo group (n = 500; 4.8 years' median follow-up). TESTING: Data were collected on demographic characteristics, medical history, ocular examination visual fields (VFs), and optic disc photographs. MAIN OUTCOME MEASURE: Development of reproducible VF abnormality or optic disc progression as determined by masked readers and attributed to POAG by a masked end point committee. RESULTS: The same predictors for the development of POAG were identified independently in both the OHTS observation group and the EGPS placebo group-baseline age, intraocular pressure, central corneal thickness, vertical cup-to-disc ratio, and Humphrey VF pattern standard deviation. The pooled multivariate model for the development of POAG had good discrimination (c statistic, 0.74) and accurate estimation of POAG risk (calibration chi2, 7.05). CONCLUSIONS: The OHTS prediction model was validated in the EGPS placebo group. A calculator to estimate the 5-year risk of developing POAG, based on the pooled OHTS-EGPS predictive model, has high precision and will be useful for clinicians and patients in deciding the frequency of tests and examinations during follow-up and advisability of initiating preventive treatment.
Authors: A Sommer; J M Tielsch; J Katz; H A Quigley; J D Gottsch; J C Javitt; J F Martone; R M Royall; K A Witt; S Ezrine Journal: N Engl J Med Date: 1991-11-14 Impact factor: 91.245
Authors: Carlos Gustavo De Moraes; Shaban Demirel; Stuart K Gardiner; Jeffrey M Liebmann; George A Cioffi; Robert Ritch; Mae O Gordon; Michael A Kass Journal: Invest Ophthalmol Vis Sci Date: 2012-04-02 Impact factor: 4.799
Authors: Daniel Meira-Freitas; Andrew J Tatham; Renato Lisboa; Tung-Mei Kuang; Linda M Zangwill; Robert N Weinreb; Christopher A Girkin; Jeffrey M Liebmann; Felipe A Medeiros Journal: Ophthalmology Date: 2013-11-26 Impact factor: 12.079